<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) is one of the major <z:e sem="disease" ids="C1720105" disease_type="Disease or Syndrome" abbrv="">complications of AIDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although several biologic aspects of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related NHL have been clarified, their sensitivity to immune system cytotoxic effectors has not been tested </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we have investigated the susceptibility of one major <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related NHL type, Burkitt's-type <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), to the cytotoxic activity of lymphokine-activated killers (LAK) and prolactin-activated killers (PAK), which were generated from peripheral blood mononuclear cells upon stimulation with interleukin-2 (in the case of LAK cells) and prolactin (in the case of PAK cells) </plain></SENT>
<SENT sid="3" pm="."><plain>The sensitivity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> to in vitro raised cytotoxic effectors was compared with that of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> variants of the general population, including <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The data show that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is susceptible to cytolysis by LAK cells, whereas both LAK and PAK cells can efficiently kill endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> showed resistance to <z:hpo ids='HP_0000001'>all</z:hpo> cytotoxic effectors tested </plain></SENT>
<SENT sid="6" pm="."><plain>Intriguingly, in the case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related and endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> suboptimal doses of interleukin-2 in combination with prolactin displayed a cytotoxic effect similar to that of LAK cells, suggesting a synergistic activity of the two agents </plain></SENT>
<SENT sid="7" pm="."><plain>Overall, these data corroborate the notion that the distinct <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> variants differ in their biologic features despite their morphologic and genetic similarity </plain></SENT>
</text></document>